Long-term carperitide treatment attenuates left ventricular remodeling in rats with heart failure after autoimmune myocarditis

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 3, 2009, Pages 232-239

  Tanaka, Komei ^a   Ito, Masahiro ^a   Kodama, Makoto ^a   Hoyano, Makoto ^a   Kimura, Shinpei ^a   Mitsuma, Wataru ^a   Hirono, Satoru ^a   Adachi, Takeshi ^b   Watanabe, Kenichi ^c   Nakazawa, Mikio ^d   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Carperitide; Heart failure; LV remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CYCLIC AMP; CYCLIC GMP; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CAPILLARY DENSITY; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CAPILLARY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; AUTOIMMUNE DISEASES; CAPILLARIES; CELL ADHESION MOLECULES; CELL SIZE; CORONARY VESSELS; CYCLIC GMP; FIBROSIS; HEART FAILURE; MALE; MICROFILAMENT PROTEINS; MYOCARDITIS; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHOPROTEINS; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 70349739597     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181b0cf50     Document Type: Article

References (32)

1. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368.
2. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun. 1984;118:131-139. (Pubitemid 14191955)
3. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature. 1988;332:78-81. (Pubitemid 18083551)
4. Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168:863-870. (Pubitemid 20164622)
5. Suga S, Nakao K, Itoh H, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of ''vascular natriuretic peptide system''. J Clin Invest. 1992;90:1145-1149.
6. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res. 2006;69:318-328.
7. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253. (Pubitemid 30490392)
8. Mann DL. Pathophysiology of Heart Failure. In: Libby P, Bonow RO, Zipes DP, et al, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA:W.B. Sanders; 2008. 541-560.
9. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446:444-448. (Pubitemid 46474597)
10. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108-2118. (Pubitemid 41134152)
11. Suzuki G, Lee TC, Fallavollita JA, et al. Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ Res. 2005;96:767-775. (Pubitemid 40559516)
12. Chen H, Levine YC, Golan DE, et al. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem. 2008;283:4439-4447.
13. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091-1100. (Pubitemid 29104501)
14. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278-284. (Pubitemid 24228320)
15. Yamahara K, Itoh H, Chun TH, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A. 2003; 100:3404-3409. (Pubitemid 36356596)
16. Park K, Itoh H, Yamahara K, et al. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology. 2008;149:483-491. (Pubitemid 351159359)
17. Massberg S, Gruner S, Konrad I, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein(VASP)-deficient mice. Blood. 2004;103:136-142. (Pubitemid 38029929)
18. Aszodi A, Pfeifer A, Ahmad M, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 2003;18:37-48. (Pubitemid 29005021)
19. Krause M, Dent EW, Bear JE, et al. Ena/VASP proteins. Annu Rev Cell Dev Biol. 2003;19:541-564.
20. Machesky LM. Putting on the brakes: a negative regulatory function for Ena/VASP proteins in cell migration. Cell. 2000;101:685-688.
21. Kayisli UA, Demir R, Erguler G, et al. Vasodilator-stimulated phosphoprotein expression and its cytokine-mediated regulation in vasculogenesis during human placental development. Mol Hum Reprod. 2002;8:1023-1030. (Pubitemid 35331807)
22. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117:3176-3179. (Pubitemid 350096973)
23. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133. (Pubitemid 40905140)
24. De Boer RA, Pinto YM, van Veldhuisen, DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities, Microcirculation. 2003;10:113-126.
25. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-1435.
26. Kashimura T, Hayashi M, Kodama M, et al. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J. 2003;44:735-744. (Pubitemid 41518974)
27. Brenner BM, Ballermann BJ, Gunning ME, et al. Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990;70:665-699. (Pubitemid 20196047)
28. Woods RL. Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide. Clin Exp Pharmacol Physiol. 2004;3:791-794. (Pubitemid 39556855)
29. Thomas CJ, Woods RL. Guanylyl cyclase receptors mediate cardiopulmonary vagal reflex actions of ANP. Hypertension. 2003;41:279-285.
30. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483-1493. (Pubitemid 47625560)
31. Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2007;49:667-674. (Pubitemid 46205046)
32. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37:1820-1826. (Pubitemid 32499965)